Concepedia
Statistics
Publications
44
Citations
2.2K
H-Index
25
Active since
1988
Affiliations
Bristol-Myers Squibb (United States)(Current)
DuPont (United States)
The Francis Crick Institute
Wilmington University
Pfizer (United States)
Jeremy H. Toyn is an author at Bristol-Myers Squibb (United States) specializing in medicine, natural sciences, and biochemistry.
Top concepts
MedicineNatural SciencesBiochemistryDrug DiscoveryPharmacologyMedicinal ChemistryMolecular BiologyCell BiologyDrug DevelopmentMolecular Pharmacology
Publications per year
1988–2019
Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor
Kevin W. Gillman, John E. Starrett, Michael F. Parker et al. · ACS Medicinal Chemistry Letters · 2010 · 183 citations
Pharmaceutical Science, Pharmacotherapy, Pharmaceutical Chemistry +19
Saccharomyces cerevisiae Is Capable of de Novo Pantothenic Acid Biosynthesis Involving a Novel Pathway of β-Alanine Production from Spermine
W. Hunter White, Paul L. Gunyuzlu, Jeremy H. Toyn · Journal of Biological Chemistry · 2001 · 175 citations · Full text
P40SDB25, a putative CDK inhibitor, has a role in the M/G1 transition in Saccharomyces cerevisiae.
Joseph Donovan, Jeremy H. Toyn, A. L. Johnson et al. · Genes & Development · 1994 · 141 citations · Full text
Molecular Biology, Temperature-sensitive Dbf2 Mutants, Putative Cdk Inhibitor +21
A counterselection for the tryptophan pathway in yeast: 5-fluoroanthranilic acid resistance
Jeremy H. Toyn, Paul L. Gunyuzlu, W. Hunter White et al. · Yeast · 2000 · 130 citations
Engineering, Biomolecular Tool, Tryptophan Pathway +19
The Dbf2 and Dbf20 protein kinases of budding yeast are activated after the metaphase to anaphase cell cycle transition.
Jeremy H. Toyn, Leland H. Johnston · The EMBO Journal · 1994 · 129 citations · Full text
Signal Transduction, Cell Regulation, Cell Division +11
1–5 of 44